Ran Cui

Dr. Ran Cui

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
RCRan Cui
Ran Cui
ZLZhongxiang Luo
Zhongxiang Luo
XZXialin Zhang
Xialin Zhang
XYXinlin Yu
Xinlin Yu
GYGang Yuan
Gang Yuan
OJOu Jiang
Ou Jiang
Phosphoinositide 3-kinases (PI3Ks), members of the lipid kinase family, play a significant role in modulating immune cell functions, including activation, proliferation, and differentiation. Recent studies have identified the PI3K signaling pathway as a key regulator in tumor biology and the immune microenvironment. This pathway enhances the activity of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), contributing to an immunosuppressive tumor microenvironment that impairs the effectiveness of cancer vaccines and immunotherapies. The present study explores PI3K isoforms, particularly p110γ and p110δ, and their associated signaling pathways. The therapeutic potential of selective PI3K inhibitors and their capacity to act synergistically with immunization strategies are analyzed. Targeting the PI3K signaling pathway represents a promising approach to counteract tumor-induced immune suppression and improve the efficacy of immune checkpoint inhibitors and vaccines, ultimately leading to better clinical outcomes.

22 November 2024 in Medicine
Verified
Journal Article
Open access
YWYongping Wang
Yongping Wang
XCXiao Chen
Xiao Chen
YLYuan Luo
Yuan Luo
CCChang Chen
Chang Chen
RCRan Cui
Ran Cui
Background: To conduct a systematic review and meta-analysis assessing the influence of K-line status on postoperative clinical outcomes in patients with cervical posterior longitudinal ligament ossification (OPLL). Methods: We searched PubMed, Embase, OVID, Cochrane Library, and Web of Science databases for English-language literature related to K-line and OPLL up to June 7, 2024. The study underwent rigorous selection, quality assessment, and data extraction, followed by meta-analysis using Review Manager 5.3 and Stata 17.0 software. This study has been registered with the international PROSPERO registry (registration number: CRD42024558578). Results: Seventeen articles encompassing 1247 patients were included. The meta-analysis revealed that patients with a positive K-line (K-line (+)) exhibited significantly enhanced Japanese Orthopaedic Association score recovery rate (mean differences [MD] = 19.28, 95% confidence interval [CI]: 12.28–26.28, P < .00001), Japanese Orthopaedic Association score (MD = 1.51, 95% CI: 0.64–2.37, P = .0007), C2-C7 Cobb angle (MD = 6.45, 95% CI: 3.73–9.17, P < .00001), alongside reduced occupation ratio (MD = −7.67, 95% CI: −10.86 to −4.49, P < .00001), C2-C7 sagittal vertical axis (MD = −6.18, 95% CI: −8.36 to −3.99, P < .00001), and neck disability index (MD = −1.85, 95% CI: −3.18 to −0.52, P = .006) at final follow-up compared to those with a negative K-line (K-line (−)). No significant differences were observed in postoperative complication rates (odds ratio = 1.15, 95% CI: 0.41–3.20, P = .79), final follow-up visual analog scale scores (MD = −0.10, 95% CI: −0.80 to 0.59, P = .77), or T1 slope (MD = 2.66, 95% CI: −0.20 to 5.52, P = .07) between the 2 groups. Conclusion: A positive preoperative K-line (K-line (+)) is a better predictor of prognosis and is associated with improved clinical outcomes in patients with multi-segmental cervical OPLL compared to a negative K-line (K-line (−)).

25 November 2022 in Medicine
Verified
Journal Article
Open access
RCRan Cui
Ran Cui
CWChun Wei
Chun Wei
XLXianyi Li
Xianyi Li
OJOu Jiang
Ou Jiang
Background: The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) in improving the prognostic outcome of non-small cell lung cancer (NSCLC) cases harboring EGFR mutation following radical surgery is still controversial. This work focused on comparing EGFR-TKIs and adjuvant chemotherapy (ACT) or placebo in treating NSCLC cases, specifically on those with EGFR-mutant, being in the stage of IB-IIIA and possibly gained benefits from the above treatment after radical resection. Methods: The Cochrane Library, MEDLINE, and Embase databases were searched to identify eligible clinical trials; two authors were responsible for screening the results. The primary outcomes were evaluated by disease-free survival (DFS) and overall survival (OS) based on hazard ratios (HRs) and a relevant 95% confidence interval (CI). Results: The literature search yielded twelve eligible studies, including four retrospective cohort studies and eight randomized controlled trials (RCTs) that enrolled 1694 cases and were of acceptable quality. In patients receiving adjuvant EGFR-TKIs compared with ACT or placebo treatment, HR regarding DFS was 0.47 (95% CI: 0.40, 0.55), whereas the OS rate was 0.74 (95% CI: 0.58, 0.95). For patients who received adjuvant EGFR-TKIs in combination with conventional chemotherapy compared to chemotherapy, the efficiency was significantly enhanced, with the HR for DFS being 0.29 (95% CI: 0.15, 0.58) and that for OS being 0.51 (95% CI: 0.25, 1.04), separately. Conclusion: For NSCLC cases who had EGFR mutations and surgery, adjuvant EGFR-TKI combined with chemotherapy achieved superior effect over chemotherapy or placebo with reference to DFS and may prolong the OS up to some extent.